DK1408106T3 - Cancer immunterapi - Google Patents

Cancer immunterapi

Info

Publication number
DK1408106T3
DK1408106T3 DK02022787T DK02022787T DK1408106T3 DK 1408106 T3 DK1408106 T3 DK 1408106T3 DK 02022787 T DK02022787 T DK 02022787T DK 02022787 T DK02022787 T DK 02022787T DK 1408106 T3 DK1408106 T3 DK 1408106T3
Authority
DK
Denmark
Prior art keywords
lymphocytes
sentinel
dukes
nodes
proliferation
Prior art date
Application number
DK02022787T
Other languages
Danish (da)
English (en)
Inventor
Ola Winqvist
Magnus Thoern
Original Assignee
Sentoclone Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sentoclone Ab filed Critical Sentoclone Ab
Application granted granted Critical
Publication of DK1408106T3 publication Critical patent/DK1408106T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0651—Lymph nodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK02022787T 2002-10-11 2002-10-11 Cancer immunterapi DK1408106T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02022787A EP1408106B1 (fr) 2002-10-11 2002-10-11 Immunothérapie du cancer

Publications (1)

Publication Number Publication Date
DK1408106T3 true DK1408106T3 (da) 2007-06-11

Family

ID=32010966

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02022787T DK1408106T3 (da) 2002-10-11 2002-10-11 Cancer immunterapi

Country Status (12)

Country Link
US (1) US8709404B2 (fr)
EP (2) EP1808200A3 (fr)
JP (2) JP5652984B2 (fr)
AT (1) ATE353954T1 (fr)
AU (1) AU2003269760B2 (fr)
CY (1) CY1106573T1 (fr)
DE (1) DE60218173T2 (fr)
DK (1) DK1408106T3 (fr)
ES (1) ES2282355T3 (fr)
NZ (1) NZ539843A (fr)
PT (1) PT1408106E (fr)
WO (1) WO2004032951A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE353954T1 (de) 2002-10-11 2007-03-15 Sentoclone Therapeutics Ab Immuntherapie für krebs
EP1444989A1 (fr) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensibilisation de cellules à l'apoptose par bloquage selective de cytokines
US20050249699A1 (en) * 2004-05-05 2005-11-10 Stoff Jesse A Immunodynamic complexes and methods for using and preparing such complexes
SG165328A1 (en) * 2005-08-31 2010-10-28 Ith Immune Therapy Holdings Ab Treatment of inflammatory bowel disease
US8211425B2 (en) 2005-12-21 2012-07-03 Sentoclone International Ab Method for treating disseminated cancer
WO2007071410A1 (fr) * 2005-12-21 2007-06-28 Sentoclone Ab Methode de traitement du cancer de la vessie
US8007785B2 (en) 2005-12-21 2011-08-30 Sentoclone International Ab Method for treating colon cancer with tumour-reactive T-lymphocytes
AU2006328945B2 (en) * 2005-12-21 2011-06-30 Sentoclone International Ab Method for treating malignant melanoma
CA2634167C (fr) * 2005-12-21 2015-06-16 Sentoclone Ab Methode amelioree pour la proliferation de lymphocytes t reactifs a une tumeur a des fins d'immunotherapie pour des patients atteints de cancer
US7951365B2 (en) * 2007-06-27 2011-05-31 Deifiera Falun Ab Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
EP3156069B8 (fr) 2008-06-20 2020-10-21 Duke University Compositions, procédés et kits permettant de provoquer une réponse immunitaire
JP2011528326A (ja) * 2008-07-18 2011-11-17 セントクローネ インターナショナル エービー インビトロ拡大されたｔリンパ球及びガン治療に適切な血管形成インヒビターを含む組成物
EP2375897A4 (fr) * 2009-01-14 2013-05-15 Health Research Inc Procédés et compositions contenant des inhibiteurs de la mtor pour améliorer les réponses immunitaires
CN110878282A (zh) * 2019-05-09 2020-03-13 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种肿瘤抗原特异性t淋巴细胞的制备方法
AU2022337186A1 (en) 2021-08-30 2025-03-06 Carrygenes Bioengineering, Llc Use of chemokine receptors in cellular homing

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311688A (en) 1979-10-29 1982-01-19 Serono Laboratories Inc. Composition and method for cancer detection in humans
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
JPH05502369A (ja) * 1989-09-14 1993-04-28 セルコ、インコーポレイテッド 養子免疫療法に用いられる生体外増殖リンパ性細胞の製造方法
US5814295A (en) 1992-04-10 1998-09-29 The Ohio State University Research Foundation Determination of lymph nodes enriched in tumor reactive cells their proliferation and their use in adoptive cellular therapy
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
ES2278390T3 (es) * 1996-05-23 2007-08-01 The Scripps Research Institute Sistema de presentacion de antigenos de clase ii de cmh y procedimientos de activacion de linfocitos t cd4+.
WO1999053949A2 (fr) 1998-04-23 1999-10-28 Arch Development Corporation Adjuvants faisant office de vaccins permettant l'immunisation contre les melanomes
AU4603499A (en) 1998-06-26 2000-01-17 Joergen Agnholt Methods of expanding and selecting disease associated t-cells
AU5905400A (en) * 1999-07-14 2001-02-05 Board Of Regents, The University Of Texas System Methods and compositions for delivery and retention of active agents to lymph nodes
GB0007088D0 (en) 2000-03-23 2000-05-17 Torsana A S Detection of immunological memory determining the position of loci of pathologyand therapeutic t-cell conjugates
US7012098B2 (en) 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
US20030228635A1 (en) * 2002-02-15 2003-12-11 Renovar, Inc. Cell proliferation assays and methods
CA2492938C (fr) 2002-08-02 2012-05-22 Joseph H. Coggin, Jr. Vaccins anticancereux contenant des epitopes d'antigene oncofoetal
US7897336B2 (en) 2002-08-16 2011-03-01 John Wayne Cancer Institute Molecular lymphatic mapping of sentinel lymph nodes
ATE353954T1 (de) 2002-10-11 2007-03-15 Sentoclone Therapeutics Ab Immuntherapie für krebs
EP1561819A4 (fr) 2002-10-24 2006-03-22 Dnavec Research Inc Procede permettant de transferer des genes dans des lymphocytes t
EP1419787A1 (fr) 2002-11-18 2004-05-19 Uwe Prof. Dr. Till Composé destiné à l'identification du ganglion lymphatique
WO2007071410A1 (fr) 2005-12-21 2007-06-28 Sentoclone Ab Methode de traitement du cancer de la vessie
US8007785B2 (en) 2005-12-21 2011-08-30 Sentoclone International Ab Method for treating colon cancer with tumour-reactive T-lymphocytes
US8211425B2 (en) 2005-12-21 2012-07-03 Sentoclone International Ab Method for treating disseminated cancer
AU2006328945B2 (en) 2005-12-21 2011-06-30 Sentoclone International Ab Method for treating malignant melanoma
CA2634167C (fr) 2005-12-21 2015-06-16 Sentoclone Ab Methode amelioree pour la proliferation de lymphocytes t reactifs a une tumeur a des fins d'immunotherapie pour des patients atteints de cancer
US7951365B2 (en) 2007-06-27 2011-05-31 Deifiera Falun Ab Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
JP2011528326A (ja) 2008-07-18 2011-11-17 セントクローネ インターナショナル エービー インビトロ拡大されたｔリンパ球及びガン治療に適切な血管形成インヒビターを含む組成物

Also Published As

Publication number Publication date
EP1408106A1 (fr) 2004-04-14
US20070141026A1 (en) 2007-06-21
WO2004032951A1 (fr) 2004-04-22
ATE353954T1 (de) 2007-03-15
EP1808200A3 (fr) 2007-09-19
CY1106573T1 (el) 2012-01-25
US8709404B2 (en) 2014-04-29
PT1408106E (pt) 2007-04-30
JP2012197260A (ja) 2012-10-18
DE60218173D1 (de) 2007-03-29
JP5946282B2 (ja) 2016-07-06
DE60218173T2 (de) 2007-11-22
EP1808200A2 (fr) 2007-07-18
AU2003269760B2 (en) 2008-08-28
EP1408106B1 (fr) 2007-02-14
AU2003269760A1 (en) 2004-05-04
ES2282355T3 (es) 2007-10-16
JP2006507262A (ja) 2006-03-02
NZ539843A (en) 2008-05-30
JP5652984B2 (ja) 2015-01-14

Similar Documents

Publication Publication Date Title
DK1408106T3 (da) Cancer immunterapi
Badalamenti et al. Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
de Bruin et al. Granzyme B-expressing peripheral T-cell lymphomas: neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue localization
Chott et al. Most CD56+ intestinal lymphomas are CD8+ CD5− T-cell lymphomas of monomorphic small to medium size histology
Bouzidi et al. Prognostic value of natural killer cells besides tumor-infiltrating lymphocytes in breast cancer tissues
Hartmann et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN‐α induction in plasmacytoid dendritic cells
Caligaris-Cappio Review Role of the microenvironment in chronic lymphocytic leukaemia.
Ogura et al. NK cells control tumor-promoting function of neutrophils in mice
Shang et al. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients
Heeg et al. Insights into phenotypic and functional CD8+ TRM heterogeneity
WO2007071389A1 (fr) Méthode de traitement de cancer disséminé
Moers et al. Regulation of CD95 (APO‐1/FAS) ligand and receptor expression in squamous‐cell carcinoma by interferon‐γ and cisplatin
Tremante et al. A melanoma immune response signature including Human Leukocyte Antigen‐E
Baba et al. Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B
Page et al. A phase Ib study of preoperative, locoregional IRX-2 cytokine immunotherapy to prime immune responses in patients with early-stage breast cancer
Mannweiler et al. Colliding/concomitant tumors of the intestine: report of 3 cases
Berti et al. Primary anaplastic large cell lymphoma of the skin
Tsuneyama et al. Expression of MAGE‐A3 in intrahepatic cholangiocarcinoma and its precursor lesions
Klein et al. Expression of HLA class I and class II in gastric carcinoma in relation to pathologic stage
Osanto et al. Downmodulation of c-myc expression by interferon γ and tumour necrosis factor α precedes growth arrest in human melanoma cells
Russell et al. USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics
Hochheiser et al. Tumor reactivity of CD8+ T cells favors acquisition of dysfunctional states in human melanoma.
Fonsatti et al. In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells
Yee Adoptive T cell therapy—immune monitoring and MHC multimers
Hussein et al. Analysis of the mononuclear inflammatory cell infiltrate in the cirrhotic, dysplastic nodules and hepatocellular carcinomas in patients with chronic hepatitis C infection